Method of producing sub-micron particles of biologically active agents and uses thereof

• US 6,428,815 B1
• Filed: 07/03/2001
• Issued: 08/06/2002
• Est. Priority Date: 10/21/1999
• Status: Expired due to Fees

• Current Assignee: Alkermes Controlled Therapeutics Inc. II (Alkermes plc)
• Original Assignee: Alkermes Controlled Therapeutics Inc. II (Alkermes plc)
• Inventors: Beganski, Christopher P., Costantino, Henry R., Jaworowicz, Warren E., Tracy, Mark A.
• Primary Examiner(s): AZPURU, CARLOS A
• Application Number:
  US09/898,524
• Publication Number:
  US 20020028252A1
• Time in Patent Office: 399 Days
• Field of Search: 424/501, 424/502, 264/4.1, 264/4.33, 264/4.6, 428/402.21
• US Class Current: 424/501
• CPC Class Codes: A61K 9/1688 resulting in pure drug agglomerate optionally containing up to 5% of excipient
• CPC Class Codes: A61K 9/1694 resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• CPC Class Codes: Y10S 977/906 Drug delivery
• CPC Class Codes: Y10T 428/2985 Solid-walled microcapsule from synthetic polymer

Abstract

Submicron particles of a biologically active agent are prepared by atomizing using multifluid atomization a dispersed system comprising at least one biologically active agent and at least one solvent to produce droplets, freezing the droplets to produce frozen droplets, lyophilizing the frozen droplets to obtain microstructures capable of being further fragmented into submicron particles by techniques such as probe sonication. The submicron particles can be incorporated into sustained release compositions having a reduced initial release of biologically active agent. The sustained release compositions can be administered to a human or animal.

Claims

1. A method for preparing a composition for the sustained release of biologically active protein comprising the steps of:

a) atomizing using multifluid atomization a dispersed system comprising at least one biologically active protein and at least one solvent at a mass flow ratio of about 0.30 or greater to produce droplets;

b) freezing the droplets to produce frozen droplets;

c) removing the solvent from the frozen droplets to produce friable microstructures;

d) dispersing the friable microstructures in at least one non-solvent for the biologically active protein;

e) fragmenting the dispersed friable microstructures to produce submicron particles of the biologically active protein;

f) providing a suspension comprising the submicron particles of the biologically active protein, at least one biocompatible polymer and at least one polymer solvent; and

g) removing the polymer solvent to form a solid polymer/protein matrix.

2. The method of claim 1 further comprising the steps of:

a) forming droplets of the polymer/protein suspension; and

b) freezing the droplets of the polymer/protein suspension wherein steps a) and b) are performed prior to removing the polymer solvent.

3. The method of claim 2 wherein the polymer solvent is removed by extraction with an extraction solvent.

4. The method of claim 1 wherein the submicron particles have a volume median particle size of less than 1 micron, measured by laser diffraction.

5. The method of claim 1 wherein the biologically active protein is present in the suspension at a concentration of from about 0.01 to about 50% w/w of the combined weight of polymer and biologically active protein.

6. The method of claim 5 wherein the biologically active protein is present in the suspension at a concentration of about 0.01 to 30% w/w of the combined weight of the polymer and biologically active protein.

7. The method of claim 1 wherein the biologically active protein is complexed to a stabilizing metal cation.

8. The method of claim 7 wherein said stabilizing metal cation is selected from the group consisting of Zn⁺², Ca⁺², Cu⁺², Mg⁺², K⁺ and any combination thereof.

9. The method of claim 8 wherein said stabilizing metal cation is Zn⁺².

10. The method of claim 1 wherein the protein is selected from human growth hormone, erythropoietin, insulin, an interferon or an interleukin.

11. The method of claim 1 wherein the protein is human growth hormone.

12. The method of claim 11 wherein the human growth hormone is complexed to Zn⁺².

13. The method of claim 1 wherein the biocompatible polymer is biodegradable.

14. The method of claim 13 wherein the biodegradable polymer is selected from the group comsisting of poly(lactide)s, poly(glycolide)s, poly(lactide-coglycolide)s, poly(lactic acis)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, poly(caprolactone), polycarbonates, polyesteramides, polyanhydrides, poly(amino acid)s, poly(ortho ester)s, polycyanoacrylates, polyamides, polyacetals, poly(ether ester)s, copolymers of poly(ethylene glycol) and poly(ortho ester)s, poly(dioxanone)s, poly(alkylene alkylate)s, biodegradable polyurethanes, blends and copolymer thereof.

15. The method of claim 14 wherein said polymer is poly(lactide-co-glycolide).

16. The method of claim 1 wherein the biocompatible polymer is non-biodegradable.

17. The method of claim 1 wherein the polymer solvent is methylene chloride, chloroform, acetone, ethyl acetate, methyl acetate, dimethylsulfoxide, hexafluoroisopropanol or any combinations thereof.

18. The method of claim 1 wherein the dispersed system further comprises a metal cation component which modulates the release of the biologically active protein from the composition for sustained release.

19. The method of claim 18 wherein the metal cation component is selected from the group consisting of mg(OH)₂, MgCO₃, CaCO₃, ZnCO₃, Mg(OAc)₂, Zn(OAc)₂, ZnSO₄, MgCl₂, ZnCl₂, MgSO₄, zinc citrate and magnesium citrate.

20. The method of claim 1 wherein the suspension further comprises a metal cation component which modulates the release of the biologically active protein from the composition for sustained release.